Amneal Pharmaceuticals, Inc

Amneal Pharmaceuticals, Inc(AMRX)股票分析

$20.200

+0.366 (+1.81%)收盘时

Loading chart…
最高
20.300
开盘
19.900
成交量加权均价
20.08
成交量
4.66M
市值
1.98B
最低
19.730
成交额
93.56M
企业价值/息税折旧摊销前利润(TTM)
11.39

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

AI 分析 of Amneal Pharmaceuticals, Inc (AMRX)

买入

Amneal Pharmaceuticals Inc is a good buy right now due to its current price of $19.18, which is significantly below the average analyst price target of $23.75 (from various analysts). The company has shown strong growth with a year-to-date change of +51.50% and a gross margin of 44.31% in Q1 2026, indicating solid profitability. The main risk is its RSI of 38.32, suggesting it is nearing oversold territory, which could lead to volatility.

估值指标

Amneal Pharmaceuticals, Inc(AMRX)当前预期市盈率为 6.30,5 年平均预期市盈率为 8.01。

预期市盈率

合理
5 年均值 P/E
8.01
当前P/E
6.30
高估
11.50
低估
4.52

预期 EV/EBITDA

严重高估
5 年均值 EV/EBITDA
7.39
当前EV/EBITDA
11.39
高估
9.01
低估
5.78

预期市销率

严重高估
5 年均值 P/S
0.69
当前P/S
1.96
高估
1.18
低估
0.20

Alphio AI 对 AMRX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AMRX

$7.49

情景价格

基

基准

基准 · 50%AMRX

$7.15

情景价格

悲

悲观

悲观 · 25%AMRX

$6.32

情景价格

持有 AMRX 的大户

R

Rubric Capital Management LP

+ 持有AMRX

+0.06%

3个月收益率

P

Paralel Advisors LLC

+ 持有AMRX

-2.15%

3个月收益率

A

Applied Finance Advisors, LLC

+ 持有AMRX

-4.08%

3个月收益率

事件时间线

2026-09-18 (ET)

16:30:00

Amneal Pharmaceuticals Receives FDA Approval for Lanreotide Injection

2026-09-03 (ET)

17:00:00

Selling Stockholders Plan to Sell 28.94M Shares of Class A Common Stock

2026-07-30 (ET)

06:31:00

Raises 2026 Revenue Outlook to $3.10B-$3.20B

06:31:00

Amneal Reports Q2 Revenue of $796M, Raises Full-Year Guidance

2026-07-17 (ET)

08:30:00

Amneal Receives FDA Approval for New iohexol Injection Strengths

资讯

AMRX 常见问题 —— 由 Alphio AI 解答

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Amneal Pharmaceuticals Inc is a good buy right now due to its current price of $19.18, which is significantly below the average analyst price target of $23.75 (from various analysts). The company has shown strong growth with a year-to-date change of +51.50% and a gross margin of 44.31% in Q1 2026, indicating solid profitability. The main risk is its RSI of 38.32, suggesting it is nearing oversold territory, which could lead to volatility.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易